We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





New Rapid 45-Minute COVID-19 Test Ideal for Screening at Points of Risk

By LabMedica International staff writers
Posted on 09 Jul 2020
Researchers at the Aikens Research Center at Beaumont Research Institute (Southfield, MI, USA) who developed the test found the results to be highly accurate as compared to existing technology. More...
Additionally, the rapid test is also relatively inexpensive to develop and operate as the materials for it are inexpensive and it does not require expensive machinery to run.

The researchers adapted the same technology for the COVID-19 test that they had come up with for a rapid, Zika virus detection test about three years ago. The detection test builds on recommendations from Anthony Fauci, M.D., immunologist and director of the National Institute of Allergy and Infectious Diseases since 1984, that rapid testing and tracing are the keys to containing the coronavirus. The researchers are now focusing on securing corporate sponsorship to fund development of the COVID-19 test.

According to Laura Lamb, Ph.D., who led the team, the test “could be used for screening at the point of risk, such as nursing homes, long-term care facilities, cruise ships, naval ships, within the school and prison systems, and by large employers, for example, at an Amazon warehouse or meatpacking plant. Because this is an existing test, we are optimistic with the right resources, it could be ready for widespread use within a month or so.”

Related Links:
Beaumont Research Institute


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.